Here, instead of using cutoffs of PD-L1 positivity, we used the CD8/FOXP3 ratio combined with both PD-1 and PD-L1 expression for stratification of NSCLC patients. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.